190 related articles for article (PubMed ID: 36270213)
1. Combination therapy in Mucormycosis: Current evidence from the world literature, a mini review.
Meena DS; Kumar D; Bohra GK
J Mycol Med; 2023 Mar; 33(1):101332. PubMed ID: 36270213
[TBL] [Abstract][Full Text] [Related]
2. Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.
Riley TT; Muzny CA; Swiatlo E; Legendre DP
Ann Pharmacother; 2016 Sep; 50(9):747-57. PubMed ID: 27307416
[TBL] [Abstract][Full Text] [Related]
3. Antifungal combinations in Mucorales: A microbiological perspective.
Schwarz P; Cornely OA; Dannaoui E
Mycoses; 2019 Sep; 62(9):746-760. PubMed ID: 30830980
[TBL] [Abstract][Full Text] [Related]
4. Mucormycosis: The hidden and forgotten disease.
Darwish RM; AlMasri M; Al-Masri MM
J Appl Microbiol; 2022 Jun; 132(6):4042-4057. PubMed ID: 35156271
[TBL] [Abstract][Full Text] [Related]
5. Contemporary management and clinical outcomes of mucormycosis: A systematic review and meta-analysis of case reports.
Jeong W; Keighley C; Wolfe R; Lee WL; Slavin MA; Chen SC; Kong DCM
Int J Antimicrob Agents; 2019 May; 53(5):589-597. PubMed ID: 30639526
[TBL] [Abstract][Full Text] [Related]
6. Role of Amphotericin B in the Treatment of Mucormycosis.
Sachdeva A; Targhotra M; Chauhan MK; Chopra M
Curr Pharm Des; 2024; 30(1):1-9. PubMed ID: 38178658
[TBL] [Abstract][Full Text] [Related]
7. An extensive review on antifungal approaches in the treatment of mucormycosis.
Chaudhari HS; Palkar OS; Abha Mishra KM; Sethi KK
J Biochem Mol Toxicol; 2023 Sep; 37(9):e23417. PubMed ID: 37345721
[TBL] [Abstract][Full Text] [Related]
8. The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK.
Bagshaw E; Kuessner D; Posthumus J; Escrig C; Blackney M; Heimann SM; Cornely OA
Future Microbiol; 2017 May; 12():515-525. PubMed ID: 28191796
[TBL] [Abstract][Full Text] [Related]
9. Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents.
Hussain MK; Ahmed S; Khan A; Siddiqui AJ; Khatoon S; Jahan S
Eur J Med Chem; 2023 Jan; 246():115010. PubMed ID: 36566630
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive use of saturated solution of potassium iodide (SSKI) with liposomal amphotericin B (L-AMB) in mucormycosis achieves favorable response, shortened dose and duration of amphotericin: A retrospective study from a COVID-19 tertiary care center.
Mrig S; Sardana K; Arora P; Narula V; Arora S; Kapoor A; Baruah RR; Sen P; Agarwal S; Sachdeva S; Dewan A; Panesar S
Am J Otolaryngol; 2022; 43(3):103465. PubMed ID: 35429848
[TBL] [Abstract][Full Text] [Related]
11. Favourable outcome in a child with acute lymphoblastic leukaemia and pulmonary mucormycosis managed with combination antifungal therapy of liposomal amphotericin B and caspofungin.
Khera S; Singh V; Pattanayak S
BMJ Case Rep; 2021 Oct; 14(10):. PubMed ID: 34667044
[TBL] [Abstract][Full Text] [Related]
12. Part 2: mucormycosis: focus on therapy.
Lynch JP; Zhanel GG
Expert Rev Anti Infect Ther; 2023; 21(7):737-748. PubMed ID: 37300820
[TBL] [Abstract][Full Text] [Related]
13. Successful nonoperative management of gastrointestinal mucormycosis: novel therapy for invasive disease.
Mezhir JJ; Mullane KM; Zarling J; Satoskar R; Pai RK; Roggin KK
Surg Infect (Larchmt); 2009 Oct; 10(5):447-51. PubMed ID: 19485785
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis.
Lewis RE; Albert ND; Liao G; Hou J; Prince RA; Kontoyiannis DP
Antimicrob Agents Chemother; 2010 Mar; 54(3):1298-304. PubMed ID: 20038620
[TBL] [Abstract][Full Text] [Related]
15. Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report.
Cornu M; Bruno B; Loridant S; Navarin P; François N; Lanternier F; Amzallag-Bellenger E; Dubos F; Mazingue F; Sendid B
BMC Pharmacol Toxicol; 2018 Dec; 19(1):81. PubMed ID: 30522521
[TBL] [Abstract][Full Text] [Related]
16. Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn).
Salmanton-García J; Seidel D; Koehler P; Mellinghoff SC; Herbrecht R; Klimko N; Ráčil Z; Falces-Romero I; Ingram P; Benítez-Peñuela MÁ; Rodríguez JY; Desoubeaux G; Barać A; García-Vidal C; Hoenigl M; Mehta SR; Cheng MP; Klyasova G; Heinz WJ; Iqbal N; Krause R; Ostermann H; Penack O; Schalk E; Sheppard DC; Willinger B; Wisplinghoff H; Vehreschild JJ; Cornely OA; Vehreschild MJGT;
J Antimicrob Chemother; 2019 Nov; 74(11):3315-3327. PubMed ID: 31393591
[TBL] [Abstract][Full Text] [Related]
17. Mucormycosis: New Developments into a Persistently Devastating Infection.
Danion F; Aguilar C; Catherinot E; Alanio A; DeWolf S; Lortholary O; Lanternier F
Semin Respir Crit Care Med; 2015 Oct; 36(5):692-705. PubMed ID: 26398536
[TBL] [Abstract][Full Text] [Related]
18. Molecular Mechanisms of Antifungal Resistance in Mucormycosis.
Ganesan P; Ganapathy D; Sekaran S; Murthykumar K; Sundramoorthy AK; Pitchiah S; Shanmugam R
Biomed Res Int; 2022; 2022():6722245. PubMed ID: 36277891
[TBL] [Abstract][Full Text] [Related]
19. Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK.
Bagshaw E; Enoch DA; Blackney M; Posthumus J; Kuessner D
Future Microbiol; 2018 Sep; 13(11):1283-1293. PubMed ID: 29911889
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of the efficacy of liposomal amphotericin B and amphotericin B deoxycholate against six species of Zygomycetes in a murine lethal infection model.
Takemoto K; Yamamoto Y; Kanazawa K
J Infect Chemother; 2010 Dec; 16(6):388-95. PubMed ID: 20535522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]